• Users Online: 21
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2018  |  Volume : 7  |  Issue : 1  |  Page : 33-38

Thyroid dysfunction in chronic myeloid leukemia patients on nilotinib


1 Department of Genetics, The Iraqi Centre for Cancer and Medical Genetic Research, Al-Mustansiriyah University, Karbala, Iraq
2 Department of Pharmacology, University of Karbala, College of Medicine, Karbala, Iraq
3 National Center of Hematology, Al-Mustansiriyah University, Baghdad, Iraq

Correspondence Address:
Dr. Khaleed J Khaleel
Department of Genetics, The Iraqi Centre for Cancer and Medical Genetic Research, Al-Mustansiriyah University, Baghdad
Iraq
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijh.ijh_39_17

Rights and Permissions

Background: The use of tyrosine kinase inhibitors has dramatically improved the prognosis of chronic myeloid leukemia (CML). Nilotinib has been reported to be associated with hypothyroidism and hyperthyroidism. Objectives: The current study aims to evaluate the prevalence of thyroid dysfunction in a sample of Iraqi patients with CML (chronic phase) treated with nilotinib and its possible association with grade of other hematological parameters. Patients and Methods: Thirty-one patients with CML and the same number of healthy controls were enrolled in this cross-sectional study. All the patients were on nilotinib hydrochloride for at least 6 months. Results: Approximately 10% of the patients were having hypothyroidism and 3% were hyperthyroid while the rest (87%) were normal regarding thyroid function. There was a significant difference between the study and control group in thyroid stimulating hormone levels (P < 0.05) with the level being higher in the study group. Conclusion: Thyroid dysfunction, particularly hypothyroidism is a clinically important adverse effect of nilotinib. Monitoring of thyroid function is required for patients taking this drug.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed894    
    Printed41    
    Emailed0    
    PDF Downloaded92    
    Comments [Add]    

Recommend this journal